Evidence map›Paper›PMID 27246107›Full record

ReviewJournal of gastroenterology2016

Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Hiroshi Fukui, Hidetsugu Saito, Yoshiyuki Ueno, Hirofumi Uto, Katsutoshi Obara, Isao Sakaida, Akitaka Shibuya, Masataka Seike, Sumiko Nagoshi, Makoto Segawa and 9 more

Registry-linked trialOpen access · bronzeAbstract readReview
PubMed Publisher
In one paragraph

Review in Journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05963776 (Pulmonary Function Tests Study in Cirrhotic Patients With and Without Hepatocellular Carcinoma), which is not on this map. Cited by 164 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
164citing papers in PubMed, 6 pooled it
21.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05963776 unknown statusnot on this mapstarted 2023, after this paper: background citation

Pulmonary Function Tests Study in Cirrhotic Patients With and Without Hepatocellular Carcinoma

TypeobservationalSponsorSohag UniversityRan2023 to 2024Enrolled40ConditionsPulmonary Complications of Liver Cirrhosis and HCCArmsspirometry
3 · Its place in the literature

Who cites it

164 citing papers in PubMed, 6 syntheses or guidelines pooled it, 314 citations in OpenAlex.

  1. Guideline
  2. [Guidelines on the management of ascites in cirrhosis (2023 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2023
    Guideline
  3. Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Pooled it
  4. Pooled it
  5. Guideline
  6. Guideline
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Article
  12. Review
  13. [Construction of a machine learning prognostic prediction model based on psoas muscle index for patients with decompensated liver cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

104 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Hiroshi FukuiDepartment of Gastroenterology, Endocrinology and Metabolism, Nara Medical University, 840 Shijo-cho, Kashihara-shi, Nara, 634-8522, Japan. hfukui@naramed-u.ac.jp.
Hidetsugu SaitoGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Yoshiyuki UenoGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Hirofumi UtoGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Katsutoshi ObaraGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Isao SakaidaGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Akitaka ShibuyaGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Masataka SeikeGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Sumiko NagoshiGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Makoto SegawaGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Hirohito TsubouchiGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Hisataka MoriwakiGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Akinobu KatoGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Etsuko HashimotoGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Kojiro MichitakaGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Toshikazu MurawakiGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Kentaro SuganoGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Mamoru WatanabeGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
Tooru ShimosegawaGuidelines Committee for creating and evaluating the ''Evidence-based clinical practice guidelines for liver cirrhosis'', Japanese Society of Gastroenterology (JSGE), K-18 Building 8F, 8-9-13, Ginza, Chuo, Tokyo, 104-0061, Japan.
The Japanese Society of Gastroenterological Surgery · JPNara Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Japanese Society of Gastroenterology revised the evidence-based clinical practice guidelines for liver cirrhosis in 2015. Eighty-three clinical questions were selected, and a literature search was performed for the clinical questions with use of the MEDLINE, Cochrane, and Igaku Chuo Zasshi databases for the period between 1983 and June 2012. Manual searching of the latest important literature was added until August 2015. The guidelines were developed with use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. This digest version in English introduces selected clinical questions and statements related to the management of liver cirrhosis and its complications. Branched-chain amino acids relieve hypoalbuminemia and hepatic encephalopathy and improve quality of life. Nucleoside analogues and peginterferon plus ribavirin combination therapy improve the prognosis of patients with hepatitis B virus related liver cirrhosis and hepatitis C related compensated liver cirrhosis, respectively, although the latter therapy may be replaced by direct-acting antivirals. For liver cirrhosis caused by primary biliary cirrhosis and active autoimmune hepatitis, urosodeoxycholic acid and steroid are recommended, respectively. The most adequate modalities for the management of variceal bleeding are the endoscopic injection sclerotherapy for esophageal varices and the balloon-occluded retrograde transvenous obliteration following endoscopic obturation with cyanoacrylate for gastric varices. Beta-blockers are useful for primary prophylaxis of esophageal variceal bleeding. The V2 receptor antagonist tolvaptan is a useful add-on therapy in careful diuretic therapy for ascites. Albumin infusion is useful for the prevention of paracentesis-induced circulatory disturbance and renal failure. In addition to disaccharides, the nonabsorbable antibiotic rifaximin is useful for the management of encephalopathy. Anticoagulation therapy is proposed for patients with acute-onset or progressive portal vein thrombosis.

Indexed as

Evidence-Based PracticeLiver CirrhosisPractice Guidelines as TopicHumansAntiviral therapyAscitesDiagnosisGastroesophageal varicesHepatic encephalopathyHepatorenal syndromeLiver cirrhosisLiver transplantNonviral cirrhosisNutritional therapy

Identifiers

PMID27246107
OpenAlexW2416980505

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.